~~<i id='1087E62E50'><strike id='1087E62E50'><tt id='1087E62E50'><pre id='1087E62E50'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：hotspot 2025-09-30 09:08:55 Page View：2

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： A single Democrat is willing to weaken Medicare negotiation power
Next article： Moonlake's readout produced a cash windfall. Risks remain

explore

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Cano Health’s bankruptcy is a warning for Medicare Advantage

AdobePrivateMedicarejustisn’tthegoldmineitoncewas.Caseinpoint:CanoHealth,acompanyoncevaluedat$4.4bil

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

The CDC's new social media misinformation war

KIRILLKUDRYAVTSEV/AFP/GettyImagesYou’rereadingthewebeditionofD.C.Diagnosis,STAT’stwice-weeklynewslet